BioWorld Asia

Nov. 23, 2005

ExonHit Therapeutics Secures Paris Alternext Market Listing

PARIS - ExonHit Therapeutics SA became the first French biotechnology company in six years to earn a stock exchange listing. (BioWorld International) Read More

EU Seeks Ground Rules For Tissue-Engineered Products

Culture Strategy Promises Unlimited Cartilage Supplies

IntegraGen Raises EUR8M In Second Financing Round

Virologist: China Hiding Size Of Avian Flu Reach, Deaths

Pfizer Picks Candidate From NicOx, Pays EUR2M Milestone

Oxford BioMedica Brings In £30M, Searches For Partner

Nordic Biotechnology Group Emulating French Measures

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 11, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...